VERA: Trutakna's launch marks a major advance in IgA nephropathy care, with strong early uptake
Trutakna launched following July approval, targeting IgA nephropathy with strong efficacy and safety data, and a broad commercial strategy. Early launch metrics are positive, with robust payer support and a focus on expanding access and dosing options.Based on Vera Therapeutics, Inc. [VERA] 12th An…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.